Geovax Labs Inc (GOVX) - News Archive

GeoVax Labs: A Bold Move in Biotechnology Secures $8.5 Million to Advance Cancer and Infectious Disease TherapiesIn a significant development for its growth and future initiatives, GeoVax Labs, Inc. (Nasdaq: GOVX), an A...

Strategic Enhancements in Vaccine Development: GeoVax Strengthens Scientific Advisory Board with Appointment of Teresa Lambe, Acclaimed Oxford Vaccine ExpertIn a significant advancement for its scientific leadership, Ge...

GeoVax Advances Gedeptin Cancer Therapy into Phase 2 Trials, Focusing on Head and Neck Cancer In a significant move for cancer therapeutics, GeoVax Labs, Inc. has unveiled plans to initiate Phase 2 clinical trials for i...

:This article reviews recent developments and market trends related to GeoVax Labs Inc., a clinical-stage biotechnology company that specializes in the development of immunotherapies and vaccines targeting cancer and in...

Geovax Labs Inc, a biotechnology company focusing on the development of immunotherapies and vaccines targeting cancers and infectious diseases, has seen a decline in its share performance in recent weeks. This decline c...

GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid RequirementAtlanta, GA - January 29, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a leading biotechnology company specializing in im...